BioCentury

7:00 AM GMT, Jun 18, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Tools & Techniques

Nuvelo's stealth target

Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has been on compounds in-licensed from third parties. Although it's been relatively silent about the internal discovery engine, NUVO maintains it has been productive. Earlier this month, the company unveiled

Read the full 523 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.